TY - JOUR
T1 - Small cell (Neuroendocrine) carcinoma of the prostate
T2 - Etiology, diagnosis, prognosis, and therapeutic implications-A retrospective study of 30 patients from the rare cancer network
AU - Stein, Moshe E.
AU - Bernstein, Zvi
AU - Abacioglu, Ufuc
AU - Sengoz, Meric
AU - Miller, Robert C.
AU - Meirovitz, Amichai
AU - Zouhair, Abadou
AU - Freixa, Salvador Villá
AU - Poortmans, Philip H.
AU - Ash, Robert
AU - Kuten, Abraham
PY - 2008/12
Y1 - 2008/12
N2 - Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage. Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with early disease achieved complete remission for a duration of 19 and 22 months. Three patients with advanced disease achieved complete remission for 6, 7, and 54 months, respectively. Twenty-five patients succumbed to massive local and/or distant failure. No patient presented with brain metastases as the initial site of relapse. Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form. Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly. Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.
AB - Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage. Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with early disease achieved complete remission for a duration of 19 and 22 months. Three patients with advanced disease achieved complete remission for 6, 7, and 54 months, respectively. Twenty-five patients succumbed to massive local and/or distant failure. No patient presented with brain metastases as the initial site of relapse. Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form. Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly. Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.
KW - Prostate
KW - Small cell carcinoma
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=59049096202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59049096202&partnerID=8YFLogxK
U2 - 10.1097/MAJ.0b013e3181731e58
DO - 10.1097/MAJ.0b013e3181731e58
M3 - Article
C2 - 19092321
AN - SCOPUS:59049096202
SN - 0002-9629
VL - 336
SP - 478
EP - 488
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 6
ER -